G
GeneCast / 臻和
Wuxi oncology multi-omics / NGS diagnostics OEM
About GeneCast / 臻和
Wuxi oncology multi-omics / NGS diagnostics OEM (GeneCast / 臻和) providing therapy-selection, MRD and early-detection panels that span next-generation sequencing, multiplex IHC/IO profiling and companion-diagnostics services for hospitals and pharmaceutical partners across China. Founded in 2014 with group headquarters in Wuxi (Xishan / 锡东创融大厦 narrative) rather than a Beijing-only Haidian shell, the company commercializes multi-omics oncology assays and CDx support for clinical and pharma channels. Mid-size China NGS leftover peer beyond Burning Rock, GenePlus and AmoyDx.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2014
- Headquarters
- Wuxi, China
- Employees
- 26
- Open positions
- None listed
- Dealroom signal
- 51.5/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Testing, Biotechnology, Oncology, DNA, Genetics and genomics, Health Diagnostics, Genome Engineering, Biotech and Pharma, Hard Tech, medical testing, proteomics, DT and LS
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES EOther financing | Oct 2020 | $149M | $596M | Hillhouse Capital · CCB International · Taiping Asset Management · China Structural Reform Fund | — |
| SERIES DOther financing | Oct 2019 | $43M | $170M | TMT Investments · Matrix Partners China · Cowin Venture · CICC | — |
Growth signals
Latest recorded traffic for GeneCast / 臻和 is 1.2K monthly website visits, up 44.6% over the last three months. GeneCast / 臻和's team grew 8.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
 Blueprint GeneticsUses Next Generation Sequencing (NGS) to perform diagnostics on genetic diseases |
Espoo, Finland | Operational | 220 | $36M | $62M |
 Probably GeneticProbably Genetic helps rare genetic disease patients get diagnosed |
San Francisco, United States | Operational | |||
 23MofangGenetics testing and analyzing Startup Based In China |
Chengdu, China | Operational | |||
 AnchorDxAnchorDx is a precision medicine firm |
Guangzhou, China | Operational | |||
 GeneAdviserOur mission is to make genetic testing for rare diseases more accessible to clinicians around the world |
Cambridge, United Kingdom | Operational | |||
 PrevnosBiotechnology company operating within the in vitro diagnostics sector |
Jersey City, United States | Operational | |||
 PierianDxEnables clinical labs to deliver patient-specific diagnosis and treatments |
St. Louis, United States | Acquired | |||
 Shield BioFighting antibiotic resistance with genomics |
Santa Clara, United States | Closed |
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Tsinghua Holdings
Series B and later10 investors entered at this stage
Loyal Valley Capital
Matrix Partners China
Cowin Venture
CICC
TMT Investments
China Structural Reform Fund
Hillhouse Capital
CCB International- TMTaiping Asset Management
China Renaissance
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about GeneCast / 臻和 on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See GeneCast / 臻和’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.